Keywords: Neuroendocrine carcinoma, Market forecasts, Avastin, Roche, BioSynthema, Lutathera, Ipsen, Somatuline, Global Data

Global neuroendocrine carcinoma market to reach $475 million by 2019; report

Article | 04 July 2012

Print This

The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market is forecast to increase at compound ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in